Back to Journals » Cancer Management and Research » Volume 5

Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies

Authors Chao MP

Received 24 April 2013

Accepted for publication 10 June 2013

Published 23 August 2013 Volume 2013:5 Pages 251—269

DOI https://doi.org/10.2147/CMAR.S34273

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3



Mark P Chao

Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA

Abstract: Over the last few decades, advances in immunochemotherapy have led to dramatic improvement in the prognosis of non-Hodgkin’s lymphoma (NHL). Despite these advances, relapsed and refractory disease represents a major treatment challenge. For both aggressive and indolent subtypes of NHL, there is no standard of care for salvage regimens, with prognosis after relapse remaining relatively poor. Nevertheless, there are multiple emerging classes of targeted therapies for relapsed/refractory disease, including monoclonal antibodies, antibody–drug conjugates, radioimmunotherapy, small-molecule inhibitors of cell-growth pathways, and novel chemotherapy agents. This review will discuss treatment challenges of NHL, current available salvage regimens for relapsed/refractory NHL, and the safety and efficacy of novel emerging therapies.

Keywords: non-Hodgkin’s lymphoma, relapsed/refractory disease, novel therapies

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.